Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 54 of 54 for:    COPD OR COPD OR chronic obstructive pulmonary disease OR chronic bronchitis OR emphysema | Recruiting, Not yet recruiting, Available Studies | NIH, U.S. Fed

Household Air Pollution and Health: A Multi-country LPG Intervention Trial (HAPIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02944682
Recruitment Status : Recruiting
First Posted : October 26, 2016
Last Update Posted : May 6, 2019
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Bill and Melinda Gates Foundation
Berkeley Air Monitoring Group
Colorado State University
Global Alliance for Clean Cookstoves
Global LPG Partnership
Harvard University
Johns Hopkins University
London School of Hygiene and Tropical Medicine
Asociación Benéfica Prisma
Sri Ramachandra University
Universidad del Valle, Guatemala
Universidad Peruana Cayetano Heredia
University of Georgia
Washington University School of Medicine
University of Rwanda
Eagle Research Center
University of Oxford
Information provided by (Responsible Party):
Thomas Clasen, Emory University

Brief Summary:
This study is a randomized controlled trial of liquefied petroleum gas (LPG) stove and fuel distribution in 3,200 households in four countries (India, Guatemala, Peru, and Rwanda). Following a common protocol, each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation), and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels, and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. The researchers estimate that 15% of households will have a second, non-pregnant older adult woman (aged 40 to <80 years) who will also be enrolled at baseline and followed during the 18-month follow-up period. To optimize intervention use, the researchers will implement behavior change strategies informed by previous experiences and formative research in Year 1. This study will assess cookstove use, conduct repeated personal exposure assessments of household air pollution, and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and blood pressure in the older adult woman. Secondary outcomes include preterm birth and development in the child, maternal blood pressure during pregnancy, and endothelial function, respiratory impairment, atherosclerosis, carcinogenic metabolites, and quality of life in the older adult woman.

Condition or disease Intervention/treatment Phase
Infant, Low Birth Weight Other: Liquefied petroleum gas (LPG) cookstove Not Applicable

Detailed Description:

Globally, nearly 3 billion people rely on solid fuels for cooking and heating, the vast majority in low- and middle-income countries (LMICs). The resulting household air pollution (HAP) is the third leading risk factor in the 2010 global burden of disease, accounting for an estimated 4.3 million deaths annually, largely among women and young children. Previous interventions have provided cleaner biomass-based cookstoves, but have failed to reduce exposure to levels that produce meaningful health improvements. There have been no large-scale field trials with liquefied petroleum gas (LPG) cookstoves, likely the cleanest scalable intervention.

The aim of this study is to conduct a randomized controlled trial of LPG stove and fuel distribution in 3,200 households in four LMICs (India, Guatemala, Peru, and Rwanda) to deliver rigorous evidence regarding potential health benefits across the lifespan. Each intervention site will recruit 800 pregnant women (aged 18-34 years, 9 - <20 weeks gestation), and will randomly assign half their households to receive LPG stoves and an 18-month supply of LPG. Control households are anticipated to continue to cook primarily with solid biomass fuels, and will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research. The mother will be followed along with her child until the child is 1 year old. In households with a second, non-pregnant older adult woman (aged 40 to <80 years) the researchers will also enroll and follow her during the 18-month follow-up period in order to assess cardiopulmonary, metabolic, and cancer outcomes. To optimize intervention use, the researchers will implement behavior change strategies. This study will assess cookstove use, conduct repeated personal exposure assessments to HAP (PM2.5, black carbon, carbon monoxide), and collect dried blood spots and urinary samples for biomarker analysis and biospecimen storage on all participants at multiple time points. The primary outcomes are low birth weight, severe pneumonia incidence, and stunting of the child, and blood pressure in the older adult woman. Secondary outcomes include preterm birth and development in the child, maternal blood pressure during pregnancy, and endothelial function, respiratory impairment, atherosclerosis, carcinogenic metabolites, and quality of life in the older adult woman.

This study will address the following specific aims: (1) using an intent-to-treat analysis, determine the effect of a randomized LPG stove and fuel intervention on health in four diverse LMIC populations using a common protocol; (2) determine the exposure-response relationships for HAP and health outcomes; and (3) determine relationships between LPG intervention and both targeted and exploratory biomarkers of exposure/health effects.

This study will provide evidence, including costs and implementation strategies, to inform national and global policies on scaling up LPG stoves among vulnerable populations. Ultimately, this will facilitate deeper policy-level discussions as well as identify requirements for initiating and sustaining HAP interventions globally.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 7200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Household Air Pollution and Health: A Multi-country LPG Intervention Trial
Actual Study Start Date : April 16, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Liquefied petroleum gas cookstove
Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
Other: Liquefied petroleum gas (LPG) cookstove
The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.

No Intervention: Control
Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.



Primary Outcome Measures :
  1. Birth weight [ Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization) ]
    Newborn weight will be assessed by a trained nurse or health worker at the <24-hour visit during the changing of newborn into pre-weighed clothing to keep the infant at least partially covered to prevent cold stress. Weight will measured to the nearest 10 g using a digital electronic scale. Calibration of scales and infantometers, using standard weight and height measures, will be done at the start of each measurement session.

  2. Incidence of Pneumonia [ Time Frame: Up to 12 months after birth ]
    The number of times that a child has pneumonia during the first one year of life will be assessed. Active surveillance for acute lower respiratory infections in infants will be conducted at home visits at 24 hours, and at 5 visits until the child reaches 12 months of age. Health workers will be trained to recognized influenza-like illness (cough or sore throat, and fever >38°C) and danger signs of pneumonia using Integrated Management of Childhood Illness (IMCI) definitions. Infants with severe acute lower respiratory infections (hypoxemia measured by portable pulse oximeter or with chest indrawing or stridor) will be referred for pulmonary ultrasound, and also referred to standard medical care.

  3. Length-for-age z-score [ Time Frame: 12 months after birth ]
    The primary outcome measured is linear growth failure, or stunting, at one year of age. Infant length will be assessed quarterly, until the child is 12 months old. Stunting will be assessed using height-for-age z-scores (HAZ) based on the 2006 World Health Organization (WHO) Child Growth Standards. Stunting is defined as HAZ <-2 standard deviations (SD) below the median z-score.

  4. Blood pressure [ Time Frame: Up to 18 months ]
    Blood pressure will be assessed in the older adult women in the intervention and control arms using automatic sphygmomanometers (OMRON M6 Comfort IT; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.


Secondary Outcome Measures :
  1. Maternal blood pressure [ Time Frame: Up to 5 months ]
    Blood pressure will be assessed in the pregnant women in the intervention and control arms using automatic sphygmomanometers (OMRON M6 Comfort IT; Osaka, Japan). The study team will use the procedures adapted from previously validated methods and cardiovascular outcome studies, following recommendations for the American Heart Association and the European Society of Hypertension.

  2. Change in fetal growth [ Time Frame: Baseline, Gestation Week 24-28 and Gestation Week 32-36 ]
    Pregnant women will have ultrasounds at Baseline and during gestation weeks 24-28 and gestation weeks 32-36 to measure fetal growth. Abnormal fetal growth will be defined as an estimated fetal weight of less than the 10th percentile for gestational age based on the recently completed international standard for fetal growth (INTERGROWTH-21st) produced by the World Health Organization (WHO).

  3. Preterm birth [ Time Frame: Up to 5 months (within 24 hours of birth, 3-5 months post randomization) ]
    Preterm birth is defined as delivery of a living infant prior to 37 completed weeks of gestation.

  4. Change in child development [ Time Frame: 3 months of age to 12 months of age ]
    Child development will be assessed with the Caregiver Reported Early Childhood Development Instrument (CREDI). The CREDI is a population-level measure of early childhood development (ECD) for children from 0-3 years of age. The CREDI assesses 5 domains of child development: 1) motor development (fine and gross motor), 2) language development (expressive and receptive language), 3) cognitive development (executive function, problem solving and reasoning, and pre-academic knowledge), 4) socio-emotional development (emotional and behavioral self-regulation, emotional knowledge, and social competence), and 5) mental health (internalizing and externalizing behaviors). The CREDI long form has 117 items and the number of questions answered depends on the age of the child. Responses of "yes" are coded as 1 and "no" is coded as 0; certain items are reverse coded. Total raw scores increase by age (with developmental progression), and higher scores indicate increased development.

  5. WHO Severe Pneumonia [ Time Frame: Up to 12 months after birth ]
    WHO defines severe pneumonia as the presence of at least one of the following: oxygen saturation less than 90%, central cyanosis, severe respiratory distress, inability to drink breastfeed or vomiting everything, altered consciousness, and convulsions. Inpatient antibiotic treatment is recommended. The number of cases of severe pneumonia, according to WHO criteria, will be recorded.

  6. Brachial artery reactivity testing (BART) [ Time Frame: 18 months ]
    Brachial artery reactivity testing (BART) measures endothelial function via flow-mediated dilatation to reactive hyperemia following the release of arm blood-flow occlusion. In this test, baseline artery diameter is measured, then a blood pressure cuff is inflated to induce distal arm ischemia for 5 minutes and after releasing the pressure, the post-occlusion brachial artery diameter is measured. The ratio of post- to pre-occlusion artery diameter represents endothelial function where lower values indicate worse endothelial function.

  7. Carotid intima-media thickness (CIMT) [ Time Frame: 18 months ]
    The carotid intima-media thickness test (CIMT) is used to determine the extent of carotid atherosclerotic vascular disease. The test measures the thickness of the inner two layers of the carotid artery and can detect plaque build up prior to physical symptoms being experienced. The carotid ultrasound will be performed with a portable ultrasound by trained sonographers.

  8. Adult respiratory health and well-being [ Time Frame: 18 months ]
    Adult respiratory health and well-being will be assessed with the St. George Respiratory Questionnaire (SGRQ). The SGRQ measures impaired health and perceived well-being among individuals with chronic airway disease. The SGRQ has sections assessing symptoms, activities that cause breathlessness or are limited because of breathlessness, and the impacts of respiratory problems on employment, sense of control of health, panic, stigmatization, medication use, side effects of therapies, expectations for health and disturbances of daily life. The questionnaire includes multiple choice, true/false and open-ended questions.

  9. Short Form 36 survey [ Time Frame: 18 months ]
    The Short Form 36 survey (SF-36) is a 36 item questionnaire evaluating quality of life. The survey has 8 sections (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health). Possible scores range from 0 (maximum disability) to 100 (no disability).


Other Outcome Measures:
  1. Change in fine particulate matter (PM2.5) exposure [ Time Frame: Up to 12 months after delivery ]
    Personal monitoring equipment will be used to assess exposure to fine particulate matter (PM2.5) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, PH2.5 in the home will be measured 6 months and 12 months after delivery of the child.

  2. Carbon monoxide (CO) exposure [ Time Frame: Up to 12 months after delivery ]
    Personal monitoring equipment will be used to assess exposure to carbon monoxide (CO) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, CO in the home will be measured 6 months and 12 months after delivery of the child.

  3. Black carbon (BC) exposure [ Time Frame: Up to 12 months after delivery ]
    Personal monitoring equipment will be used to assess exposure to black carbon (BC) over a 24-hour period in intervention and control participants (pregnant women, older adult women, and children). Exposure for pregnant women will be measured at baseline, 24-28 weeks gestation, and 32-36 weeks gestation. Additionally, BC in the home will be measured 6 months and 12 months after delivery of the child.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for Pregnant Women:

  • Confirmed pregnancy (hCG positive blood or urine test)
  • Aged 18 to <35 years (via self-report)
  • Uses biomass stove predominantly
  • Lives in study area
  • 9 - <20 weeks gestation confirmed by ultrasound
  • Singleton pregnancy (one fetus)
  • Viable fetus with normal fetal heart rate (120-180 beats per minute) at time of ultrasound
  • Continued pregnancy at the time of randomization confirmed by self-report
  • Agrees to participate with informed consent

Exclusion Criteria for Pregnant Women:

  • Currently smokes cigarettes or other tobacco products
  • Plans to move permanently outside study area in the next 12 months
  • Uses LPG stove predominantly, or is likely to use LPG predominantly in the near future

Inclusion Criteria for Older Adult Woman in the Same Household:

  • Aged 40 to <80 years (via self-report)

Exclusion Criteria for Older Adult Woman in the Same Household:

  • Currently smokes cigarettes or other tobacco products
  • Pregnant (by self-report)
  • Plans to move out of her current household in the next 12 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02944682


Contacts
Layout table for location contacts
Contact: Thomas Clasen, PhD 404-727-3480 thomas.f.clasen@emory.edu

Locations
Layout table for location information
Guatemala
Universidad del Valle de Guatemala Recruiting
Guatemala, Guatemala, 01015
Contact: John McCracken    +502 23298492      
India
Sri Ramachandra University Recruiting
Chennai, Tamil Nadu, India, 600116
Contact: Kalpana Balakrishnan    91-44-2476-7008      
Peru
Puno Global Non-Communicable Disease Research Site, School of Medicine, Johns Hopkins University Recruiting
Puno, Peru
Contact: William Checkley    443-287-8741      
Rwanda
Rwanda Research Site, London School of Hygiene and Tropical Medicine Recruiting
Kigali, Rwanda
Contact: Maria Abadie Rosa    +44 207 927 2686      
Sponsors and Collaborators
Emory University
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Bill and Melinda Gates Foundation
Berkeley Air Monitoring Group
Colorado State University
Global Alliance for Clean Cookstoves
Global LPG Partnership
Harvard University
Johns Hopkins University
London School of Hygiene and Tropical Medicine
Asociación Benéfica Prisma
Sri Ramachandra University
Universidad del Valle, Guatemala
Universidad Peruana Cayetano Heredia
University of Georgia
Washington University School of Medicine
University of Rwanda
Eagle Research Center
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Thomas Clasen, PhD Emory University
Principal Investigator: Jennifer Peel, PhD Colorado State University
Principal Investigator: William Checkley, MD PhD Johns Hopkins School of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Thomas Clasen, Professor, Emory University
ClinicalTrials.gov Identifier: NCT02944682     History of Changes
Other Study ID Numbers: IRB00089799
1UM1HL134590-01 ( U.S. NIH Grant/Contract )
First Posted: October 26, 2016    Key Record Dates
Last Update Posted: May 6, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Thomas Clasen, Emory University:
Obstetrics
Pregnancy Outcomes
Pediatrics
Atherosclerosis
Cancer
Cardiovascular Disease
Public Health
Environmental Air Pollutants
Additional relevant MeSH terms:
Layout table for MeSH terms
Birth Weight
Body Weight
Signs and Symptoms